2022 Biosimilars Insurance Coverage and Processing 
Pharma in Brief
FEBRUARY 2, 2022
The feedback will inform a stakeholder session in spring 2022 and the Panel’s final report. In Canada, coverage for prescription drugs exists through an array of public and private drug plans. The Panel is seeking input from stakeholders on or before February 25, 2022 via an online questionnaire. Background. a formulary); and.
Big Molecule Watch
AUGUST 25, 2023
Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Putting Patients First Blog
JANUARY 27, 2025
Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.
PharmaShots
JUNE 28, 2023
The decrease in Enbrel sales for 2022 was primarily driven by unfavorable changes to estimated sales deductions, lower volume, and lower net selling prices. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. Enbrel biosimilars Gabionline.net Centerforbiosimilars.com 7.
FDA Law Blog: Biosimilars
OCTOBER 29, 2023
Since that blog post, an important step forward was the decoupling of the coverage requirement from the FDA Birth Control Guide in the guidance provided by the Department to plans and issuers.
Expert insights. Personalized for you.
59 
Let's personalize your content